NYSEAMERICAN:PFNX - Pfenex Stock Price, Forecast & News

Pfenex trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PFNX."

Pfenex Inc (NYSEAMERICAN:PFNX) posted its quarterly earnings data on Thursday, November, 7th. The biotechnology company reported $0.09 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.09. The biotechnology company had revenue of $15.25 million for the quarter, compared to the consensus estimate of $14.80 million. View Pfenex's Earnings History.

Pfenex is scheduled to release their next quarterly earnings announcement on Monday, March 9th 2020. View Earnings Estimates for Pfenex.

4 brokers have issued 12 month price objectives for Pfenex's stock. Their forecasts range from $17.00 to $20.00. On average, they expect Pfenex's stock price to reach $18.50 in the next twelve months. This suggests a possible upside of 74.2% from the stock's current price. View Analyst Price Targets for Pfenex.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pfenex in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Pfenex.

News stories about PFNX stock have trended very negative on Monday, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Pfenex earned a media sentiment score of -3.0 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for Pfenex.

Pfenex saw a increase in short interest in October. As of October 15th, there was short interest totalling 890,400 shares, an increase of 68.3% from the September 15th total of 529,100 shares. Based on an average daily trading volume, of 320,500 shares, the short-interest ratio is currently 2.8 days. Approximately 2.8% of the shares of the stock are sold short. View Pfenex's Current Options Chain.

Some companies that are related to Pfenex include Clinuvel Pharmaceuticals (CUV), Concordia International (CXR), Polynovo (PNV), Mesoblast (MSB), Immutep (IMM), Paradigm Biopharmaceuticals (PAR), BELLUS Health (BLU), Oxford BioMedica (OXB), Starpharma (SPL), Silence Therapeutics (SLN), TELIX Pharmaceutical (TLX), Biotest (BIO), Bellus Health (BLU), Neptune Wellness Solutions (NEPT) and Rafael (RFL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Pfenex investors own include Ocular Therapeutix (OCUL), Fate Therapeutics (FATE), Opko Health (OPK), Relypsa (RLYP), Spectrum Pharmaceuticals (SPPI), TherapeuticsMD (TXMD), Verastem (VSTM), Alder Biopharmaceuticals (ALDR), Coherus Biosciences (CHRS) and Dicerna Pharmaceuticals (DRNA).

Pfenex's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include State Street Corp (1.74%), Millennium Management LLC (0.82%), Squarepoint Ops LLC (0.55%), Russell Investments Group Ltd. (0.48%), Commonwealth Equity Services LLC (0.25%) and Point72 Asset Management L.P. (0.24%). Company insiders that own Pfenex stock include Evert B Schimmelpennink, Patrick K Lucy, Phillip M Schneider and Robin Campbell. View Institutional Ownership Trends for Pfenex.

PFNX stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Strs Ohio, Man Group plc, Zurcher Kantonalbank Zurich Cantonalbank, Commonwealth Equity Services LLC and Barclays PLC. View Insider Buying and Selling for Pfenex.

PFNX stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, Squarepoint Ops LLC, Point72 Asset Management L.P., State Street Corp, Delta Investment Management LLC, Metropolitan Life Insurance Co NY, California Public Employees Retirement System and California State Teachers Retirement System. Company insiders that have bought Pfenex stock in the last two years include Evert B Schimmelpennink, Phillip M Schneider and Robin Campbell. View Insider Buying and Selling for Pfenex.

Shares of PFNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of PFNX stock can currently be purchased for approximately $10.62.

Pfenex has a market capitalization of $336.40 million. Pfenex employs 71 workers across the globe.View Additional Information About Pfenex.

The official website for Pfenex is http://www.pfenex.com/.

Pfenex's mailing address is 10790 Roselle St, SAN DIEGO, CA 92121-1508, United States. The biotechnology company can be reached via phone at +1-858-3524400.